TechMediaBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference

NanoViricides (NYSE American: NNVC), a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, will be participating at the inaugural EF Hutton Global Conference. The two-day event is scheduled for May 10–11, 2023, in New York City. Company president Anil R. Diwan, PhD, will be presenting at the gathering; his presentation is scheduled May 10. The global conference is an elite, invitation-only event featuring key executives from some 150 public and private companies; company executives are invited to present the unique stories of their companies to institutional investors, high-net worth individuals, corporate clients and members of the press; one-on-one meetings are also available during the conference. According to the announcement, companies from an array of industries will be presenting; sectors represented include consumer and retail, energy and infrastructure, financial services, healthcare and life sciences, industrials, real estate, gaming, lodging, sustainability, technology, media and telecommunications.

To view the full press release, visit https://ibn.fm/fS8L9

About NanoViricides Inc.

NanoViricides is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Each nanoviricide drug is designed so that virus variants would be highly unlikely to escape the drug, solving a critical issue in antiviral drug development. The company’s lead drug candidate for the treatment of COVID and long COVID caused by SARS-CoV-2 coronavirus is approved to enter human clinical trials that are expected very soon. The company’s other advanced candidate is NV-HHV-1 for the treatment of shingles, which has completed IND-enabling safety/pharmacology studies. NV-CoV-2 is the company’s nanoviricide drug candidate for COVID. NV-CoV-2-R is another drug candidate for COVID that is made up of NV-CoV-2 with Remdesivir, an already approved drug, encapsulated within its polymeric micelles. Remdesivir is developed by Gilead. The company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently. The company is also developing a broad pipeline of drugs against a number of viruses, with preclinical safety and effectiveness successes achieved already in many cases. For more information about the company, please visit www.NanoViricides.com

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
Editor@TechMediaWire.com

TechMediaWire is part of IBN.